<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028257</url>
  </required_header>
  <id_info>
    <org_study_id>P 210641</org_study_id>
    <secondary_id>2021-003155-42</secondary_id>
    <nct_id>NCT05028257</nct_id>
  </id_info>
  <brief_title>Allergy and COVID-19 Vaccines</brief_title>
  <acronym>COVALL</acronym>
  <official_title>Pursuit of Vaccination in Anaphylactic Reaction to COVID19 Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective monocentric study designed firstly to estimate the proportion of patients who&#xD;
      tolerated the continuation of the COVID-19 2nd injection (absence of anaphylactic&#xD;
      manifestations).&#xD;
&#xD;
      secondly, to know the proportion of definite anaphylactic reactions in cases of suspected&#xD;
      anaphylaxis after the first administration of a COVID-19 vaccine the very complete&#xD;
      allergological explorations with both the clinical side, skin tests and biological tests will&#xD;
      allow us to highlight the responsibility or not of the components of the vaccine,in&#xD;
      particular of the excipients (PEG2000, PS80 and tromethamine) in anaphylactic reactions to&#xD;
      COVID-19 vaccines A biological collection will be set up during this clinical study in order&#xD;
      to study the immunological mechanisms; the effector cells and the signalling pathways&#xD;
      involved in these reactions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients who experience an anaphylactic reaction after the first COVID-19 vaccine&#xD;
      injection as part of their routine vaccination will be identified through the hotline set up&#xD;
      by our expert center.&#xD;
&#xD;
      Three to five weeks after the anaphylactic reaction, the patients will be called for a&#xD;
      consultation in the dermatology and allergology department of Tenon hospital for a complete&#xD;
      allergological check-up.&#xD;
&#xD;
      Then, in the framework of a collegial meeting ,the patient's file will be reviewed in order&#xD;
      to specify the history of the allergic disease and the modalities of subsequent COVID-19&#xD;
      vaccination.&#xD;
&#xD;
      A follow-up telephonique call at 6months will be made systematically for patients who have&#xD;
      received the 2nd dose of vaccine to ensure thatthere are no significant adverse events&#xD;
      related to the COVID-19 vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the continuation of vaccination and its tolerance in case of negative allergological investigation.</measure>
    <time_frame>from Week 9 to Month 9</time_frame>
    <description>Proportion of patient without anaphylactic reaction during second vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the involvement of excipients in anaphylactic reactions</measure>
    <time_frame>from Week 9 to Month 9</time_frame>
    <description>Proportion of patient with positive skin tests for excipients (PEG2000, PS80) or COVID-19 vaccines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine with certainty the diagnosis of anaphylaxis in the face of a suspected anaphylactic reaction during the first administration of a COVID-19 vaccine.</measure>
    <time_frame>from Week 9 to Month 9</time_frame>
    <description>Proportion of patient with positive allergological explorations (anamnesis, skin tests or biological test for excipients or vaccines)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Anaphylactic Reaction</condition>
  <condition>Vaccine Reaction</condition>
  <arm_group>
    <arm_group_label>COVID-19 Vaccinated Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccines</intervention_name>
    <description>Pursuit of vaccination in case of anaphylactic reaction</description>
    <arm_group_label>COVID-19 Vaccinated Patients</arm_group_label>
    <other_name>Janssen COVID19 vaccine</other_name>
    <other_name>Astra Zeneca COVID19 vaccine</other_name>
    <other_name>Comirnaty Pfizer COVID19 vaccine</other_name>
    <other_name>Moderna COVID19 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Anaphylactic reaction at least 3 weeks old prior to allergology consultation, when&#xD;
             administered a COVID-19 vaccine.&#xD;
&#xD;
        Anaphylactic reaction is defined as the occurrence within hours of administration of a&#xD;
        COVID-19 vaccine of any of the following systemic manifestations; skin rash such as&#xD;
        urticaria and/or angiodema, associated with respiratory signs (dyspnea, bronchospasm,&#xD;
        desaturation), and/or digestive disorders (severe abdominal pain, diarrhea, vomiting,&#xD;
        nausea), and/or neurological disorders (loss of consciousness, feeling of faintness),&#xD;
        and/or hypotension, tachycardia.&#xD;
&#xD;
          -  Affiliation to a Social Security system&#xD;
&#xD;
          -  Signature of the informed consent&#xD;
&#xD;
          -  Stop taking antihistamines at least 3 days before skin allergy tests are performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other non-anaphylactic systemic reactions after administration of COVID-19 mRNA&#xD;
             vaccine (serum sickness, vasculitis, Guillain-Barré syndrome)&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Disorders of hemostasis or severe bleeding considered a contraindication to&#xD;
             intramuscular injection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angèle SORIA, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angèle SORIA, PUPH</last_name>
    <phone>0156017220</phone>
    <email>angele.soria@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annick BARBAUD</last_name>
    <phone>0156017220</phone>
    <email>annick.barbaud@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tenon Hospital APHP dermatology and allergology department</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angèle SORIA, PU-PH</last_name>
      <phone>0156017220</phone>
      <email>angele.soria@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Annick BARBAUD, PU-PH</last_name>
      <phone>0156017220</phone>
      <email>annick.barbaud@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anaphylactic reactions</keyword>
  <keyword>COVID-19 vaccines</keyword>
  <keyword>PEG2000</keyword>
  <keyword>tromethamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Anaphylaxis</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

